Skip to main content Skip to main content
Private-Credit Borrower

DNAnexus, Inc

DNAnexus provides a cloud platform for biomedical data analysis and management, used by pharmaceutical, diagnostic, and research organizations to process and collaborate on genomic, multi-omic, and clinical datasets at scale. Founded in 2009 as a Stanford spinout and headquartered in Mountain View, California, it serves thousands of platform users across dozens of countries and completed a $200 million financing led by Blackstone Growth in March 2022.

Company profile compiled from public sources (company filings, rating-agency reports, and press releases) — distinct from the SEC Schedule-of-Investments pricing data below.

1
BDC Lender
2
Debt Positions

Lenders

DNAnexus, Inc is held by 1 BDC lender in our parsed SEC filings: TCPC.

Cross-lender loan pricing

Each row is one debt tranche at the BDC’s most recent filing that holds this borrower, widest spread first. Mark is the position’s fair value as a percent of par (100 = par). Spread is shown in basis points over the benchmark in the Rate column, normalized from each filing’s as-reported units — rows quoting different benchmarks are still not directly comparable. Compare like-for-like: a second-lien tranche, a different vintage, or an older filing should price wider even when the credit view is identical — check the Type and Filing columns before reading a gap as disagreement. Source: SEC EDGAR (public).

BDCTypeRateCash spread (bps)Mark (% of par)Fair ValueMaturityFiling
TCPC1L Sr SecuredSOFR52599.2$1M2029-12-182026-08-06
TCPC1L Sr SecuredSOFR52599.2$7M2029-12-202026-08-06

Marks reflect each BDC’s own fair-value estimates as reported to the SEC, not traded prices. Private-credit loans are predominantly Level 3 under ASC 820 — valued from unobservable inputs and determined in good faith by each BDC’s board, so figures are estimates as of the filing date and are not directly comparable across managers. Informational only; not investment advice or a valuation.

Ownership & deal activity

No acquisition, ownership-change, or refinancing headlines for DNAnexus, Inc are in our verified news index yet. Most BDC borrowers are private companies, so ownership events are not always public; absence reflects our indexing coverage, not the borrower’s deal activity.

Headlines mentioning DNAnexus, Inc

We haven’t indexed any headlines that name DNAnexus, Inc. That reflects our news-indexing coverage — not the borrower’s activity — so the absence is not a signal.

Reading this table

When two business development companies lend to the same borrower, comparing how each marks the loan is a starting question, not a verdict. In plain English: a wider spread (e.g. S+575 vs S+525) or a lower mark (e.g. 96 vs 100 cents on the dollar) can mean that lender is pricing in more risk — but marks can also differ for reasons other than a credit view: a different tranche (second lien should price wider than first lien on the same company), a different vintage or entry point, an older filing date, or each manager’s own fair-value methodology. Compare like-for-like — check the Type and Filing columns before reading a gap as disagreement. Each row is one debt position at one BDC’s most recent filing. Source: SEC EDGAR Schedule of Investments (public).

Want to read these numbers like an analyst? Free Oxford Ledge lessons: reading a BDC’s Schedule of Investments, key credit metrics, and the Five Cs of credit analysis.